Nyxoah Q2 operating loss widens to EUR 20.59 million; revenue more than doubled to EUR 7.68 million vs Q2 FY25
NYXH•Q2 revenue rises, but losses widen
Nyxoah posted Q2 net sales of EUR 7.7 million, up from EUR 1.3 million a year earlier; US net sales rose 22% sequentially to EUR 5.2 million.
Operating loss widened to EUR 20.6 million from EUR 19.9 million; loss attributable to shareholders deepened to EUR 33.0 million from EUR 20.6 million.
Gross margin slipped to 60% from 63%, while cash, cash equivalents and financial assets climbed to EUR 97.8 million at June 30 from EUR 48.0 million at end-2025.
US rollout accelerates, guidance maintained
The US rollout accelerated with 89 new centers activated to 180 high-volume active centers; 55 new surgeons trained lifted the total to 262.
Full-year 2026 net sales outlook was maintained at EUR 36 million to EUR 40 million; total operating expenses guidance was raised to .
